300750 Contemporary Amperex Technology (A)

DGAP-News: Lifequest World Corp Subsidiary Biopipe Global Corp Enters into 50-50 Joint Venture with Abrimix Europe BV to Introduce its 100% Sludge & Chemical Free Sewage Wastewater System in Africa

DGAP-News: Lifequest World Corp / Key word(s): Miscellaneous
Lifequest World Corp Subsidiary Biopipe Global Corp Enters into 50-50 Joint Venture with Abrimix Europe BV to Introduce its 100% Sludge & Chemical Free Sewage Wastewater System in Africa
13.11.2019 / 14:09
The issuer is solely responsible for the content of this announcement.


RIDGEFIELD PARK, NJ / ACCESSWIRE / November 13, 2019 / Biopipe Global Corp., a wholly-owned subsidiary of Lifequest World Corp (OTC PINK:LQWC) has entered into a 50-50 joint venture with Abrimix Europe BV to expand into Africa with initial focus on South Africa where Abrimix is based. Water-stressed countries that also have sewage treatment deficit like South Africa, represent a large addressable market for Biopipe's 100% sludge free, chemical free, and odor free sewage wastewater treatment system. Abrimix has a commercially proven state of the art industrial wastewater treatment technology which Biopipe will introduce in countries it is currently active in.

"Sustainable access to safe drinking water and basic sanitation is an important part of the millennium development goals as set by the United Nations. (MDGs), states Pieter Jansen, CEO of Abrimix. Current practices in Africa are insufficient to address this challenge. We have found in Biopipe, the perfect complementary partner. Innovating technologies are a part of the solution and Biopipe is certainly within that spectrum. Since Biopipe is a standalone system, it is a sustainable, scalable and easy to implement solution where investment for sanitation infrastructure is not materializing. In my home country, South Africa, 50,000 liters of untreated sewage is released every second into the environment and with Biopipe we can contribute to solving this problem. We have already identified several projects to start with and present problems with water security add to the sense of urgency."

"With Abrimix and Biopipe as two innovative companies together more non-sewage wasterwater applications for Biopipe are under investigation. In the Netherlands, we are looking at using Biopipe to clean the effluent of the Abrimix Manure / digestate treatment process. In South Africa, we are looking at adding Biopipe to treat Abrimix effluent from wineries. All in all very exciting developments and we are looking forward to playing a growing part in solutions for sewage wastewater challenges specifically and water security for Africa in general."

Enes Kutluca, the CEO of Biopipe said, "We are excited to have Abrimix as a joint venture partner. South Africa in particular, but Africa in general represents a massive opportunity for Biopipe and Abrimix. With Abrimix we are able to address both industrial and sewage wastewater markets. We are looking forward leveraging Abrimix's infrastructure and Pieter's experience to begin implementing projects immediately."

About Biopipe

Biopipe, a wholly owned subsidiary of Lifequest, has developed a patented 100% sludge free, chemical free, odor free, silent, easy to assemble and install, scalable, low cost, ecological and virtually maintenance free sewage wastewater treatment system. The treated water exceeds EU Standards for discharge and can be reused for irrigation, flushing and cleaning.



Contact: or

About Abrimix

Abrimix has developed a unique patented, affordable, efficient and cost-effective technology for industrial wastewater treatment. Abrimix is able to develop, design, build and install tailor-made treatment process for specific wastewater influents. Abrimix is now active and represented in North America, Canada, South America, Europe, United Kingdom as well as within countries throughout Africa.

Contact:

Pieter Jansen

Tel: (+27) 11 463 4463
Unit 30 Kya Sand Industrial Village
22 Elsecar Street Kya Sand
South Africa

This press release contains forward-looking statements that reflect the Company's current beliefs, expectations or intentions regarding future events. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as "will," "will be," "anticipate," "predict," "expect" "continue," "future," and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: future revenues, expenditures, capital, the adequacy of the Company's current cash and working capital to fund present and planned operations, and the growth through joint ventures. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, can be found in our current Disclosure Statements at . The Company anticipates that subsequent events and developments may cause views and expectations to change. The Company assumes no obligation, and specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Lifequest World Corp


News Source: Issuer Direct


13.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


Language: English
Company: Lifequest World Corp
United States
EQS News ID: 911847

 
End of News DGAP News Service

911847  13.11.2019 

fncls.ssp?fn=show_t_gif&application_id=911847&application_name=news&site_id=research_pool
EN
13/11/2019

Underlying

300750Contemporary Amperex Technology (A)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Contemporary Amperex Technology (A)

 PRESS RELEASE

DGAP-News: ADL Bionatur Solutions Wins New Fermentation Client With Co...

DGAP-News: ADL Bionatur Solutions / Key word(s): Agreement ADL Bionatur Solutions Wins New Fermentation Client With Contract Revenues of EUR 20 Million 02.12.2019 / 09:06 The issuer is solely responsible for the content of this announcement. ADL BIONATUR SOLUTIONS WINS NEW FERMENTATION CLIENT WITH CONTRACT REVENUES OF EUR 20 MILLION The agreement with a leading Swiss biotech company includes technology transfer, upscaling and industrial-scale production of high value-added innovative ingredients for the cosmetics and nutrition industry ADL to apply its expertise in a...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: Dozens Savings Plc 5.00% Secured Bonds due 2 December 2020 ISIN: GB00BL1GTZ11  Symbol: DS04 EMS: 1 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   W...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: SAPO PLC Ordinary Shares of GBP 0.01 ISIN: GB00B16GQJ90 Symbol: SAPO EMS: 5000 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   Website: ...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publishes open letter to Dr. Martin Haefner...

EQS Group-News: Dynamics Group AG / Key word(s): Statement/Corporate Action LIWET HOLDING AG publishes open letter to Dr. Martin Haefner in various Swiss Sunday newspapers 01.12.2019 / 05:59 Open letter to Dr. Martin Haefner Dear Mr Haefner We share your concern about the future of Schmolz+Bickenbach (S+B). The company urgently needs money, everyone - including Liwet - agrees. However, there is still time to find a constructive solution for S+B that is in the interest of all, not only one particular shareholder. Liwet is ready to rescue the company and the 10,000 jobs. Liw...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haef...

EQS Group-News: Dynamics Group AG / Schlagwort(e): Stellungnahme/Kapitalmaßnahme LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haefner in verschiedenen Schweizer Sonntagszeitungen 01.12.2019 / 05:59 Offener Brief an Dr. Martin Haefner Sehr geehrter Herr Haefner Wir teilen Ihre Sorge um die Zukunft von Schmolz+Bickenbach (S+B). Die Firma braucht dringend Geld; damit sind alle - auch Liwet - einverstanden. Noch bleibt Zeit, um eine konstruktive Lösung für S+B zu finden, die im Interesse aller Aktionäre ist, nicht nur eines einzigen. Liwet steht bereit, die Fir...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch